Dr. Arvanian reports on the discoveries in his lab that he believes will improve transmission of signals in the damaged spinal cord. After identifying NG-2 as the specific CSPG blocking conduction in chronic SCI, he and his collaborators have developed an NG-2 antibody and are now working on delivery methods.